ADVFN - Advanced Financial Network.
HOME» NASDAQ » M » MYL Stock Price » MYL Stock News

Mylan Inc. Share News

 Mylan Inc. (mm) Stock Price
MYL Stock Price
 Mylan Inc. (mm) Stock Chart
MYL Stock Chart
 Mylan Inc. (mm) Stock News
MYL Stock News
 Mylan Inc. (mm) Company Information
MYL Company Information
 Mylan Inc. (mm) Stock Trades
MYL Stock Trades

Mylan Confirms Endo Suit Over Generic Migraine Drug Application

DOW JONES NEWSWIRES Mylan Inc. (MYL) confirmed Wednesday that it has been sued by Endo Pharmaceuticals Holdings Inc. (ENDP) over its application for approval of a generic drug used to treat acute migraine headaches in adults. Mylan--one of the world's largest generic drug makers--said it believes it is the first company to file a substantially complete application for approval of frovatriptan succinate EQ, a generic version of Frova. The company said it expects to qualify for 180 days of marketing exclusivity upon final approval from the Food and Drug Administration. Mylan, which has had litigation-related charges figure prominently in its recent quarterly results, last month reported second-quarter earnings surged 70% as sales got a lift from a weaker dollar. Shares closed Tuesday at $20.01 and were inactive in recent premarket trade. Through the latest close, the stock is down 5.3% since the start of the year. -By Mia Lamar, Dow Jones Newswires; 212-416-3207; mia.lamar@dowjones.com

Stock News for Mylan Inc. (MYL)
DateTimeHeadline
09/26/201620:10:00Mylan's EpiPen Pretax Profits 60% Higher Than Number Told to...
09/26/201612:09:56Current Report Filing (8-k)
09/26/201611:50:00Mylan Clarifies EpiPen Profit Figures it Provided to Congress...
09/21/201610:50:00Mylan CEO to Shift Blame on EpiPen Pricing at Hearing
09/14/201623:20:00EpiPen Maker Executive to Testify at House Hearing
09/11/201623:20:00Starboard Value Takes 4.6% Stake in Perrigo
09/06/201617:23:20Amended Current Report Filing (8-k/a)
09/06/201617:23:14Current Report Filing (8-k)
09/01/201615:12:00Mylan Invalidates Third Teva Copaxone® 40 mg/mL Patent Via U.S...
09/01/201608:20:00EpiPen Maker Mylan Tied Pay to Aggressive Profit Targets
08/29/201608:10:00Mylan, Feeling Heat on EpiPen Price, Will Offer Cheaper Generic
08/29/201606:00:00Mylan to Launch First Generic to EpiPen® Auto-Injector at a...
08/25/201609:45:00U.S. Hot Stocks: Hot Stocks to Watch
08/25/201608:30:00Mylan Boosts Price Assistance for EpiPen Amid Backlash
08/25/201607:00:00Mylan Taking Immediate Action to Further Enhance Access to EpiPen®...
08/25/201606:30:00Mylan and Biocon Announce Regulatory Submission for Proposed...
08/24/201618:20:00Mylan Faces Scrutiny Over EpiPen Price Increases
08/24/201616:47:00Mylan Invalidates Two of Teva's Copaxone® 40 mg/mL Patents Via...
08/11/201619:02:12Statement of Changes in Beneficial Ownership (4)
08/11/201617:17:24Current Report Filing (8-k)

Mylan Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad